Nautilus Biotechnology said researchers can now measure AKT1 and EGFR proteoforms at no charge, removing a cost barrier to this area of proteomics. The offer centers on phosphorylation patterns tied to cancer signaling; terms and duration were not disclosed.
published
Nautilus Biotechnology said researchers can now measure AKT1 and EGFR proteoforms at no charge, removing a cost barrier to this area of proteomics. The offer centers on phosphorylation patterns tied to cancer signaling; terms and duration were not disclosed.
Latest documented BWB result
$APP market result
Sold the $280 10/9 Calls on $APP for $7.80
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.